Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period from June 1, 2007, to November 7, 2007. The document serves as a Block Listing Six Monthly Return, detailing the status of various share option schemes and the movement of unallotted securities under these plans.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document is strictly limited to reporting the number of securities available, increased, and issued under specific employee share option schemes.
Material Changes in Share Option Schemes
The filing reports activity across nine distinct share option schemes. Key movements include:
- GlaxoSmithKline Share Option Plan - Ordinary Shares: The block was increased by 5,000,000 shares. 493,671 shares were issued, resulting in an ending balance of 2,490,262 unallotted securities.
- GlaxoSmithKline Share Option Plan - ADS: The block was increased by 32,000,000 shares. 3,628,546 shares were issued, resulting in an ending balance of 2,609,136 unallotted securities.
- Glaxo Wellcome UK Share Option Scheme: No increase in the block. 90,408 shares were issued, leaving 5,119,750 unallotted.
- Glaxo Wellcome International Share Option Scheme: No increase in the block. 315,380 shares were issued, leaving 13,267,156 unallotted.
- Glaxo Group Limited Share Option Scheme: The block was increased by 679 shares. No shares were issued, resulting in a zero balance.
- SmithKline Beecham 1989 Executive Share Option Plan - Unapproved - Ordinary Shares: The block was increased by 163,812 shares. No shares were issued, resulting in an ending balance of 100,000.
- Other Schemes: The Glaxo Wellcome 1999 Share Option Plan, SmithKline Beecham 1989 Executive Share Option Plan (Approved - Ordinary Shares), SmithKline Beecham 1989 Executive Share Option Plan (Unapproved - ADS), and GlaxoSmithKline Savings Related Share Option Scheme saw no increases in their blocks, with varying levels of issuance.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory compliance report regarding share option inventory.
Important Facts for Investors to Verify
- Significant increases in the share option pool occurred for the primary Ordinary Shares (5,000,000) and ADS (32,000,000) plans.
- Total issuance across all schemes during the period was approximately 4.6 million shares.
- The Glaxo Group Limited Share Option Scheme was fully utilized or adjusted to a zero balance.
- This filing contains no financial performance data; investors should refer to Form 20-F or quarterly earnings releases for revenue and profit metrics.